• Je něco špatně v tomto záznamu ?

Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort

K. Gisslander, A. White, L. Aslett, Z. Hrušková, P. Lamprecht, J. Musiał, J. Nazeer, J. Ng, D. O'Sullivan, X. Puéchal, M. Rutherford, M. Segelmark, B. Terrier, V. Tesař, M. Tesi, A. Vaglio, K. Wójcik, MA. Little, AJ. Mohammad, FAIRVASC consortium

. 2024 ; 6 (11) : e762-e770. [pub] 20240822

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003692

BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a heterogenous autoimmune disease. While traditionally stratified into two conditions, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the subclassification of ANCA-associated vasculitis is subject to continued debate. Here we aim to identify phenotypically distinct subgroups and develop a data-driven subclassification of ANCA-associated vasculitis, using a large real-world dataset. METHODS: In the collaborative data reuse project FAIRVASC (Findable, Accessible, Interoperable, Reusable, Vasculitis), registry records of patients with ANCA-associated vasculitis were retrieved from six European vasculitis registries: the Czech Registry of ANCA-associated vasculitis (Czech Republic), the French Vasculitis Study Group Registry (FVSG; France), the Joint Vasculitis Registry in German-speaking Countries (GeVas; Germany), the Polish Vasculitis Registry (POLVAS; Poland), the Irish Rare Kidney Disease Registry (RKD; Ireland), and the Skåne Vasculitis Cohort (Sweden). We performed model-based clustering of 17 mixed-type clinical variables using a parsimonious mixture of two latent Gaussian variable models. Clinical validation of the optimal cluster solution was made through summary statistics of the clusters' demography, phenotypic and serological characteristics, and outcome. The predictive value of models featuring the cluster affiliations were compared with classifications based on clinical diagnosis and ANCA specificity. People with lived experience were involved throughout the FAIRVASVC project. FINDINGS: A total of 3868 patients diagnosed with ANCA-associated vasculitis between Nov 1, 1966, and March 1, 2023, were included in the study across the six registries (Czech Registry n=371, FVSG n=1780, GeVas n=135, POLVAS n=792, RKD n=439, and Skåne Vasculitis Cohort n=351). There were 2434 (62·9%) patients with GPA and 1434 (37·1%) with MPA. Mean age at diagnosis was 57·2 years (SD 16·4); 2006 (51·9%) of 3867 patients were men and 1861 (48·1%) were women. We identified five clusters, with distinct phenotype, biochemical presentation, and disease outcome. Three clusters were characterised by kidney involvement: one severe kidney cluster (555 [14·3%] of 3868 patients) with high C-reactive protein (CRP) and serum creatinine concentrations, and variable ANCA specificity (SK cluster); one myeloperoxidase (MPO)-ANCA-positive kidney involvement cluster (782 [20·2%]) with limited extrarenal disease (MPO-K cluster); and one proteinase 3 (PR3)-ANCA-positive kidney involvement cluster (683 [17·7%]) with widespread extrarenal disease (PR3-K cluster). Two clusters were characterised by relative absence of kidney involvement: one was a predominantly PR3-ANCA-positive cluster (1202 [31·1%]) with inflammatory multisystem disease (IMS cluster), and one was a cluster (646 [16·7%]) with predominantly ear-nose-throat involvement and low CRP, with mainly younger patients (YR cluster). Compared with models fitted with clinical diagnosis or ANCA status, cluster-assigned models demonstrated improved predictive power with respect to both patient and kidney survival. INTERPRETATION: Our study reinforces the view that ANCA-associated vasculitis is not merely a binary construct. Data-driven subclassification of ANCA-associated vasculitis exhibits higher predictive value than current approaches for key outcomes. FUNDING: European Union's Horizon 2020 research and innovation programme under the European Joint Programme on Rare Diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003692
003      
CZ-PrNML
005      
20250206104621.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2665-9913(24)00187-5 $2 doi
035    __
$a (PubMed)39182506
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gisslander, Karl $u Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden. Electronic address: karl.gisslander@med.lu.se
245    10
$a Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort / $c K. Gisslander, A. White, L. Aslett, Z. Hrušková, P. Lamprecht, J. Musiał, J. Nazeer, J. Ng, D. O'Sullivan, X. Puéchal, M. Rutherford, M. Segelmark, B. Terrier, V. Tesař, M. Tesi, A. Vaglio, K. Wójcik, MA. Little, AJ. Mohammad, FAIRVASC consortium
520    9_
$a BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a heterogenous autoimmune disease. While traditionally stratified into two conditions, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the subclassification of ANCA-associated vasculitis is subject to continued debate. Here we aim to identify phenotypically distinct subgroups and develop a data-driven subclassification of ANCA-associated vasculitis, using a large real-world dataset. METHODS: In the collaborative data reuse project FAIRVASC (Findable, Accessible, Interoperable, Reusable, Vasculitis), registry records of patients with ANCA-associated vasculitis were retrieved from six European vasculitis registries: the Czech Registry of ANCA-associated vasculitis (Czech Republic), the French Vasculitis Study Group Registry (FVSG; France), the Joint Vasculitis Registry in German-speaking Countries (GeVas; Germany), the Polish Vasculitis Registry (POLVAS; Poland), the Irish Rare Kidney Disease Registry (RKD; Ireland), and the Skåne Vasculitis Cohort (Sweden). We performed model-based clustering of 17 mixed-type clinical variables using a parsimonious mixture of two latent Gaussian variable models. Clinical validation of the optimal cluster solution was made through summary statistics of the clusters' demography, phenotypic and serological characteristics, and outcome. The predictive value of models featuring the cluster affiliations were compared with classifications based on clinical diagnosis and ANCA specificity. People with lived experience were involved throughout the FAIRVASVC project. FINDINGS: A total of 3868 patients diagnosed with ANCA-associated vasculitis between Nov 1, 1966, and March 1, 2023, were included in the study across the six registries (Czech Registry n=371, FVSG n=1780, GeVas n=135, POLVAS n=792, RKD n=439, and Skåne Vasculitis Cohort n=351). There were 2434 (62·9%) patients with GPA and 1434 (37·1%) with MPA. Mean age at diagnosis was 57·2 years (SD 16·4); 2006 (51·9%) of 3867 patients were men and 1861 (48·1%) were women. We identified five clusters, with distinct phenotype, biochemical presentation, and disease outcome. Three clusters were characterised by kidney involvement: one severe kidney cluster (555 [14·3%] of 3868 patients) with high C-reactive protein (CRP) and serum creatinine concentrations, and variable ANCA specificity (SK cluster); one myeloperoxidase (MPO)-ANCA-positive kidney involvement cluster (782 [20·2%]) with limited extrarenal disease (MPO-K cluster); and one proteinase 3 (PR3)-ANCA-positive kidney involvement cluster (683 [17·7%]) with widespread extrarenal disease (PR3-K cluster). Two clusters were characterised by relative absence of kidney involvement: one was a predominantly PR3-ANCA-positive cluster (1202 [31·1%]) with inflammatory multisystem disease (IMS cluster), and one was a cluster (646 [16·7%]) with predominantly ear-nose-throat involvement and low CRP, with mainly younger patients (YR cluster). Compared with models fitted with clinical diagnosis or ANCA status, cluster-assigned models demonstrated improved predictive power with respect to both patient and kidney survival. INTERPRETATION: Our study reinforces the view that ANCA-associated vasculitis is not merely a binary construct. Data-driven subclassification of ANCA-associated vasculitis exhibits higher predictive value than current approaches for key outcomes. FUNDING: European Union's Horizon 2020 research and innovation programme under the European Joint Programme on Rare Diseases.
650    _2
$a lidé $7 D006801
650    12
$a ANCA-asociované vaskulitidy $x klasifikace $x diagnóza $x epidemiologie $x krev $x imunologie $7 D056648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a shluková analýza $7 D016000
650    _2
$a kohortové studie $7 D015331
650    _2
$a dospělí $7 D000328
650    _2
$a mikroskopická polyangiitida $x klasifikace $x epidemiologie $x krev $x diagnóza $x imunologie $7 D055953
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a White, Arthur $u School of Computer Science and Statistics, Trinity College Dublin, Dublin, Ireland; ADAPT Centre, Trinity College Dublin, Dublin, Ireland
700    1_
$a Aslett, Louis $u Department of Mathematical Sciences, Durham University, Durham, UK
700    1_
$a Hrušková, Zdenka $u Department of Nephrology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Lamprecht, Peter $u Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany
700    1_
$a Musiał, Jacek $u II Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Nazeer, Jamsheela $u ADAPT Centre, Trinity College Dublin, Dublin, Ireland
700    1_
$a Ng, James $u School of Computer Science and Statistics, Trinity College Dublin, Dublin, Ireland
700    1_
$a O'Sullivan, Declan $u ADAPT Centre, Trinity College Dublin, Dublin, Ireland
700    1_
$a Puéchal, Xavier $u National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France; French Vasculitis Study Group, Paris, France
700    1_
$a Rutherford, Matthew $u School of Infection and Immunity, University of Glasgow, Glasgow, UK
700    1_
$a Segelmark, Mårten $u Department of Clinical Sciences, Lund University and Department of Endocrinology, Nephrology and Rheumatology, Skåne University Hospital, Lund, Sweden
700    1_
$a Terrier, Benjamin $u National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France; French Vasculitis Study Group, Paris, France
700    1_
$a Tesař, Vladimir $u Department of Nephrology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Tesi, Michelangelo $u Nephrology and Dialysis Unit, Azienda Ospedaliera Universitaria Meyer IRCCS, Florence, Italy
700    1_
$a Vaglio, Augusto $u Nephrology and Dialysis Unit, Azienda Ospedaliera Universitaria Meyer IRCCS, Florence, Italy; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
700    1_
$a Wójcik, Krzysztof $u II Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Little, Mark A $u ADAPT Centre, Trinity College Dublin, Dublin, Ireland; Trinity Kidney Centre, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland
700    1_
$a Mohammad, Aladdin J $u Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden; Department of Medicine, University of Cambridge, Cambridge, UK
710    2_
$a FAIRVASC consortium
773    0_
$w MED00214733 $t The Lancet. Rheumatology $x 2665-9913 $g Roč. 6, č. 11 (2024), s. e762-e770
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39182506 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104617 $b ABA008
999    __
$a ok $b bmc $g 2263448 $s 1239699
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 6 $c 11 $d e762-e770 $e 20240822 $i 2665-9913 $m The Lancet. Rheumatology $n Lancet Rheumatol $x MED00214733
LZP    __
$a Pubmed-20250121
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace